Vera Goode, MD
Internal Medicine · Virginia Beach, VANPI 1023081965
Payments from drug & device makers
Across 314 payments — averaging $28.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Novo Nordisk$1K
- AstraZeneca$834
- Lilly USA, LLC$423
- GSK$345
- Otsuka America Pharmaceutical, Inc.$345
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$3,36038%
- Food & beverage$5,40161%
- Education$731%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 44 | $4,078 |
| Novo Nordisk | 66 | $1,094 |
| AstraZeneca | 49 | $834 |
| Lilly USA, LLC | 29 | $423 |
| GSK | 19 | $345 |
| Otsuka America Pharmaceutical, Inc. | 15 | $345 |
| Pfizer | 18 | $327 |
| Astellas Pharma US Inc | 6 | $162 |
| Mylan Specialty L.p. | 8 | $110 |
| Boehringer Ingelheim | 7 | $103 |
| Abbott | 5 | $99 |
| Merck | 5 | $80 |
| Amarin Pharma, Inc. | 4 | $73 |
| Sunovion Pharmaceuticals Inc. | 4 | $61 |
| Novartis | 4 | $60 |
| Nevro Corp. | 2 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Gilead | 2 | $52 |
| Sumitomo Pharma America, Inc. | 2 | $49 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Exact Sciences | 2 | $45 |
| Boston Scientific | 3 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Amgen | 2 | $33 |
| Eisai Inc. | 1 | $26 |
| Almatica Pharma LLC | 1 | $24 |
| Phadia US Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$3,360
How this compares
$8,834 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 26 | $39,070 |
| EliquisApixaban | 30 | $33,980 |
| JardianceEmpagliflozin | 28 | $32,760 |
| JanuviaSitagliptin Phosphate | 14 | $22,262 |
| LinzessLinaclotide | 11 | $8,996 |
| Clonidine | 15 | $3,810 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,778 |
| Atorvastatin Calcium | 130 | $1,786 |
| Valsartan | 27 | $1,447 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 17 | $1,438 |
| Rosuvastatin Calcium | 103 | $1,318 |
| Metoprolol Succinate | 64 | $1,200 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 46 | $1,177 |
| Levothyroxine Sodium | 59 | $1,059 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 22 | $769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,094 | $39,07026 claims |
| PfizerEliquis | $327 | $33,98030 claims |
| Boehringer IngelheimJardiance | $103 | $32,76028 claims |
| MerckJanuvia | $80 | $22,26214 claims |
| AbbVieLinzess, Synthroid | $4,078 | $9,47631 claims |
| Almatica Pharma LLCSertraline Hcl | $24 | $22134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Virginia Beach
- Garfield SamuelsVirginia Beach$124K
- Anita KumarVirginia Beach$72K
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.